Total retail prescription drug sales for 1999 are expected to exceed $121.6 billion.
Total retail prescription drug sales for 1999 are expected to exceed $121.6 billion, according to a study released by the National Association of Chain Drug Stores. The estimate is an 18% increase over the 1998 year-end level of $103.5 billion. NACDS also projects an 8% increase in the number of prescriptions dispensed in retail pharmacies.
According to the study, 2.97 billion prescriptions will have been dispensed by year's end.
Several factors are responsible for the increases, according to Phil Schneider, the managing director of public affairs for the NACDS. "Demographics, product introduction, recognition of the role of medicines in treating illnesses earlier and quicker and advertising can make patients more informed or cause them to seek more health care," explained Schneider.
Schneider cautioned that the figures must be looked at in relation to health care costs as a whole.
"Frequently people say 'rise in the cost of prescription drugs' and they mean rise in prescription drug expenditures," Schneider said. "There are two components in the rise of prescription drug expenditures: the increase in the number of prescriptions and the price of those prescriptions. So while overall prescription expenditures may be increasing in the 10% to 12% rate, total health care expenditures are not increasing at that level." PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.